Principal Investigator: Charalampos Tzoulis

We recently completed the NAD-PARK study, a trial of tolerability and cerebral bioavailability of NAD supplementation therapy with NR in PD (ClinicalTrials.gov: NCT03816020). A total of 30 individuals with newly diagnosed, drug naïve PD were randomized to NR 500 mg x2/day or placebo for 30 days. Link to the scientific publication: The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease – PubMed (nih.gov)